Systemic Lupus Erythematosus – Vasculitis/DAH
❖ ~1.5M patients in US with SLE
❖ 16,000 new cases/yr
❖ No curative Rx to date
❖ US market size $1.87B annually
❖ Acute lupus nephritis and diffuse alveolar hemorrhage (DAH) with >70% mortality
❖ SLE growing at ~7% per year, large unmet
❖ Market Opportunity
❖ FDA-Approved Therapies for SLE
❖Anti-Malarials, Steroids, MTX, Benlysta (B Lymph, beluminab) & Saphnelo™ (IFN, August 2021), Rituximab (CD20)
